Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
update ??
Thoughts on tomorrows open?
I gotta be honest, I started getting the regret feeling and now I see filings!
I think we will see some whales tomorrow forsure
Nice little rebound right before close...cant be green everyday. Just means shares are going to Longs
Its still early...anything can happen.
Let us know if you find out anything
Still waiting for mine
Great to have you here...how did you find out about VPRO?
my 0.03 alert just went off!
Oh just another company Ivor Royston brought to buyout!
SAN FRANCISCO (MarketWatch) - Biotechnology company Corixa Corp. said after the closing bell Friday that has agreed to be acquired by British pharmaceutical giant GlaxoSmithKline Plc for $4.40 a share in cash, or $300 million.
After being halted, shares of Corixa rose to $4.20 in after-hours trading from a regular-session close at $3.09.
Corixa said the $4.40-a-share price represents a 48% premium over its closing share price of $2.98 on Thursday.
Seattle-based Corixa CRXA worked with GlaxoSmithKline GSK, +1.05% (GSK) to develop Bexxar, a drug used to treat non-Hodgkin's lymphoma, as well as on other projects aimed at discovering and developing vaccine adjuvants and antigens.
Glaxo, in a separate statement, said it owns about 8% of Corixa shares and that the deal is of particular importance to its vaccines division.
Glaxo said one of the key features of the deal is the acquisition of Corixa's manufacturing facility in Hamilton, Mont., the production site of Monophosphoryl Lipid A, or MPL, an adjuvant contained in a number of vaccines in Glaxo's pipeline.
One of Glaxo's candidate vaccines is Cervarix, aimed at targeting infection with Human Papilloma Virus, one of the leading causes of cervical cancer.
The transaction is expected to close during the third quarter.
Shares of GlaxoSmithKline closed up 1.6% at $50.55 before the announcement.
This is just Impressive!!!!
Eli Lilly to Buy Applied Molecular of San Diego
Eli Lilly & Co. agreed Friday to buy Applied Molecular Evolution of San Diego for $400 million in cash and stock.
Big drug companies have increasingly been turning to small biotechnology firms to stock their product development pipelines.
Applied Molecular, founded in 1989, has no products, but it is working on second-generation versions of popular biotechnology drugs, including Genentech Inc.'s Rituxan for cancer and Johnson & Johnson Inc.'s Remicade for rheumatoid arthritis.
Lilly said that it would pay $18 a share for Applied Molecular and that 80% of the total price would be in Lilly stock. The deal, which requires the approval of Applied Molecular shareholders, should close in the first quarter of 2004, the companies said.
In Nasdaq trading Friday, Applied Molecular's shares soared $5.99, or 51%, to $17.75. Lilly ended the day at $69.61, down $1.92, or 2.7%, on the New York Stock Exchange.
Listing Requirements for All Companies
Each company must have a minimum of 1,250,000 publicly-traded shares upon listing, excluding those held by officers, directors or any beneficial owners of more then 10% of the company. In addition, the regular bid price at time of listing must be $4, and there must be at least three market makers for the stock. However, a company may qualify under a closing price alternative of $3 or $2 if the company meets varying reequirements. Each listing firm is also required to follow Nasdaq corporate governance rules 4350, 4351 and 4360. Companies must also have at least 450 round lot (100 shares) shareholders, 2,200 total shareholders, or 550 total shareholders with 1.1 million average trading volume over the past 12 months.
In addition to these requirements, companies must meet all of the criteria under at least one of the following standards.
Listing Standard No. 1
The company must have aggregate pre-tax earnings in the prior three years of at least $11 million, in the prior two years at least $2.2 million, and no one year in the prior three years can have a net loss.
Listing Standard No. 2
The company must have a minimum aggregate cash flow of at least $27.5 million for the past three fiscal years, with no negative cash flow in any of those three years. In addition, its average market capitalization over the prior 12 months must be at least $550 million, and revenues in the previous fiscal year must be $110 million, minimum.
Listing Standard No. 3
Companies can be removed from the cash flow requirement of Standard No. 2 if the average market capitalization over the past 12 months is at least $850 million, and revenues over the prior fiscal year are at least $90 million.
A company has three ways to get listed on the Nasdaq, depending on the underlying fundamentals of the company. If a company does not meet certain criteria, such as the operating income minimum, it has to make it up with larger minimum amounts in another area like revenue. This helps to improve the quality of companies listed on the exchange.
It doesn't end there. After a company gets listed on the market, it must maintain certain standards to continue trading. Failure to meet the specifications set out by the stock exchange will result in its delisting. Falling below the minimum required share price, or market capitalization, is one of the major factors triggering a delisting. Again, the exact details of delisting depend on the exchange.
Read more: What are the listing requirements for the Nasdaq? | Investopedia http://www.investopedia.com/ask/answers/121.asp#ixzz3wtqLSx4o
Follow us: Investopedia on Facebook
Always coming through with valuable information! I agree, that VPRO will be on that page....I plan to look up what those companies were trading for prior to buy out...maybe get a ball park estimate for VPRO...Have a great weekend TEAM.
I think we will get some type if news by next week and a nickel by Fridays close Imo
Must say I'm pretty excited for Monday's open. I think theres gunna be some serious volume...might see 3s
Im in the same boat....still learning the stock market slang....I also stumbled across this stock using Etrade's stock screener...I guess you can say Im a Long haul holder. Welcome aboard!
Does this mean shareholders own 915.1M of the 1.2B shares?
Great information
Trades are looking good so far
We get stronger everyday as we get closer to filings. Im a smaller share holder here and increasing my position as funds allow. Im in it to win it.
sure is glad I increased my postion this morning. I also agree once 02s come....
back in the green!
no worries we will have the last laugh
hopefully in the green soon...got an order placed at market and nothing yet...
someone sold this morning? That why the drop?
Im in for the long haul. I will be increasing my position in the morning. This company has a strong group of BOD's.
Pretty sure 2's coming tomorrow. I can see $ now.
I believe today is just the start of this eruption...buckle up and enjoy the climb. 0.02 tomorrow...
Lets hope for a 0.02 close or better
Its looking good this morning...seen the drop, then right back up it went...
I used Etrade's stock screener....seen VPRO was up like 800% in 52 weeks...then I did some small research on the company's BOD's.
Finally up to 8500 shares...I know its not as many as yall, but im gettin there..this is literally my first investment ever. Still lots to learn. Thanks for all the help. VPRO all the way!
What would be a good price to set at? Not too worried about the cheapest possible price...in for the long haul
is 0.0138 a good spot to buy at? I placed a limit order at that price...
Thanks for the warm welcome "Third"...taking advantage of the drop so i can buy more shares....only currenly got 4700 shares....
New Invester here! Any tips are appreciated...